RHOH and adenocarcinoma: In the subgroup of patients with wild-type EGFR adenocarcinoma, the median OS of patients with TTF-1 positive expression was significantly longer compared to those with TTF-1 negative expression (13.6 months vs. 5.8 months, p = 0.005).